Vir Biotechnology (VIR) FCF Margin (2018 - 2026)
Vir Biotechnology (VIR) posted FCF Margin of 457848.28% for Q1 2026, down 1118506.58% sequentially from 40.93% in Q4 2025, and down 45521816.0% YoY from N/an in Q1 2025.
Vir Biotechnology (VIR) FCF Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported FCF Margin for 9 years, with the latest figure at 457848.28% in Q1 2026.
- Quarterly FCF Margin fell 45521816.0% year-over-year to 457848.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 685.92% (up 133764.0% YoY) and the FY2025 annual result came in at 578.52%, up 3283.0% from the prior year.
- FCF Margin retreated to 457848.28% in Q1 2026 per VIR's latest filing, from 40.93% in the prior quarter.
- Over five years, FCF Margin peaked at 2312.48% in Q2 2022 and troughed at 457848.28% in Q1 2026.
- A 5-year average of 33316.42% and a median of 724.34% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2026: FCF Margin soared 794723 bps in 2024, then sank 45521816 bps in 2026.
- Over 5 years, FCF Margin stood at 45.64% in 2022, then tumbled by 1529 bps to 652.06% in 2023, then retreated by 11 bps to 724.34% in 2024, then soared by 94 bps to 40.93% in 2025, then plunged by 1118507 bps to 457848.28% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 457848.28%, 40.93%, and 69952.92% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 51.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.60% |
| Mar 31, 2026 | -457,848.28% |
| Dec 31, 2025 | -40.93% |
| Sep 30, 2025 | -69,952.92% |
| Jun 30, 2025 | -10,111.78% |
| Mar 31, 2025 | -2,630.11% |
| Dec 31, 2024 | -724.34% |
| Sep 30, 2024 | -7,321.34% |
| Jun 30, 2024 | -2,553.27% |
| Mar 31, 2024 | -215.21% |
| Dec 31, 2023 | -652.06% |
| Sep 30, 2023 | -6,045.59% |
| Jun 30, 2023 | -10,500.50% |
| Mar 31, 2023 | -210.70% |
| Dec 31, 2022 | 45.64% |
| Sep 30, 2022 | 26.41% |
| Jun 30, 2022 | 2,312.48% |
| Mar 31, 2022 | 43.35% |
| Dec 31, 2021 | -1.22% |
| Sep 30, 2021 | -103.77% |